Evidence map›Paper›PMID 38004664›Full record

ArticleMicroorganisms2023

Taxifolin as a Metallo-β-Lactamase Inhibitor in Combination with Augmentin against Verona Imipenemase 2 Expressing

Bogdan M Benin, Trae Hillyer, Aylin S Crugnale, Andrew Fulk, Caitlyn A Thomas, Michael W Crowder, Matthew A Smith, Woo Shik Shin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Bogdan M BeninDepartment of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA.ORCID 0000-0002-6502-8237
Trae HillyerDepartment of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
Aylin S CrugnaleDepartment of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
Andrew FulkDepartment of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
Caitlyn A ThomasDepartment of Chemistry and Biochemistry, Miami University, Oxford, OH 45056, USA.
Michael W CrowderDepartment of Chemistry and Biochemistry, Miami University, Oxford, OH 45056, USA.ORCID 0000-0002-3138-0283
Matthew A SmithDepartment of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
Woo Shik ShinDepartment of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, OH 44272, USA.ORCID 0000-0001-6292-4733
Northeast Ohio Medical University · USMiami University · USAkron Children's Hospital · US

Funding

Magnetothermal brain stimulation towards the rescue of beta-amyloid pathologyR01AG076699 · NIA · KENT STATE UNIVERSITY · PI Min Ho Kim · 2022 to 2026
$1.9M
Machine Learning Approach for finding novel metallo-b-lactamase inhibitorsR15GM134454 · NIGMS · MIAMI UNIVERSITY OXFORD · PI CROWDER, MICHAEL W · 2019 to 2022
$867k
NIA NIH HHS R01 AG076699NIGMS NIH HHS R15 GM134454NIH HHS 1R01AG076699
6 · The paper itself

Abstract

Among the various mechanisms that bacteria use to develop antibiotic resistance, the multiple expression of β-lactamases is particularly problematic, threatening public health and increasing patient mortality rates. Even if a combination therapy-in which a β-lactamase inhibitor is administered together with a β-lactam antibiotic-has proven effective against serine-β-lactamases, there are no currently approved metallo-β-lactamase inhibitors. Herein, we demonstrate that quercetin and its analogs are promising starting points for the further development of safe and effective metallo-β-lactamase inhibitors. Through a combined computational and in vitro approach, taxifolin was found to inhibit VIM-2 expressing

Indexed as

combination therapycomputer-aided drug designESKAPE pathogensflavonolmetallo-β-lactamasesnatural productsPseudomonas aeruginosaquercetintaxifolinVIM-2

Identifiers

PMID38004664
PMCPMC10673258
OpenAlexW4388020742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.